Fagron Sterile Services (FSS) Competitors, Revenue and Alternatives

Claim your profile


Wichita, KS USA
Total Funding:N/A
Lead Investor(s):N/A

Industry Ranking

State Ranking

Estimated Revenue & Financials

  • Fagron Sterile Services (FSS)'s estimated annual revenue is currently $15.9M per year.
  • Fagron Sterile Services (FSS)'s estimated revenue per employee is $201,000

Employee Data

  • Fagron Sterile Services (FSS) has 79 Employees.
  • Fagron Sterile Services (FSS) grew their employee count by 13% last year.
  • Fagron Sterile Services (FSS) currently has 1 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingPricing
Sparhawk Labora...
Sekisui XenoTec...
Fagron Sterile ...
cGMP Validation...
KCAS Bioanalyti...
American Colleg...
ProPharma Group
Missing a competitor? Contribute!?

Fagron Sterile Services (FSS) operates FDA-registered 503B Outsourcing Facilities that provide sterile preparations produced with state-of-the-art automation and industry-leading quality control systems. We specialize in Sterile-to-Sterile, API-to-Sterile, and Biologics, offering an expansive portfolio of preparations including IV admixtures, OR syringes, pain management, ophthalmics, dialysis, urology, and adjunct solutions. OUR STORY: Fagron is leading the future of compounding by optimizing and innovating personalized pharmaceutical care. Founded in 1990, in the Netherlands, Fagron engineered one of the largest quality networks, with certified auditors performing supplier qualifications, serving 34 countries, to provide superior products for more than 200,000+ customers worldwide. In doing so, Fagron has become one of the world's leading pharmaceutical companies dedicated to safe, quality, compounding. In 2010, Fagron entered the North American market. As part of the only vertically integrated pharmaceutical company dedicated to sterile compounding, our 503B facilities drive pharmaceutical outsourcing solutions on a comprehensive level to meet customer needs across the continuum of care. As a forward-thinking pharmaceutical supplier, Fagron recognized the opportunity to serve our customers better by acquiring JCB Laboratories, in December, 2013. JCB has been at the forefront of shaping industry standards in sterile preparations for nearly two decades, and was one of the first companies in the country to register with the FDA. Building off JCB's experience, Fagron built FSS, our state-of-the-art manufacturing facility, because we believe in the need for regulated sterile preparations. We offer significant capabilities in research, development, manufacturing, and distribution. Choose Quality. Choose Consistency. Choose Fagron Sterile Services, A Solution You Can Rely On!



Number of Employees


Revenue (est)


Current Jobs


Employee Growth %


Total Funding







Executive Contacts

Jose GomezDirector Of Quality AssuranceEmail Available
Jared HothanDirector Of EngineeringEmail Available
Mark SpinelliDirector, ValidationEmail Available
Michael LawrenceRegional Account Manager
Robert DunpheyVice President of SalesEmail Available
Kate KeltzDirector Supply ChainEmail Available
Brett BeverickDirector of SalesEmail Available
Chris KirkesRegional Director of Sales - West
Carl WoetzelPresidentEmail Available
Kelly FlackCustomer Configuration, Pricing and Contract Administration ManagerEmail Available

Fagron Sterile Services (FSS) News

11/27/2018 - Collaboration Drives Company Growth At Fagron Sterile ...

WICHITA, Kan., Nov. 27, 2018 /PRNewswire/ -- Fagron Sterile Services/JCB Laboratories (FSS/JCB), a leading FDA Registered 503B ...

06/20/2017 - JCB Laboratories And Fagron Sterile Services Secure Group ...

WICHITA, Kan., June 20, 2017 /PRNewswire/ -- JCB Laboratories (JCB) and Fagron Sterile Services (FSS), companies of Fagron North ...